## <sup>1</sup>**Plasma p-tau212 as a biomarker of sporadic and Down Syndrome Alzheimer's**

## <sup>2</sup>**disease**

- 
- 4 Przemysław R. Kac\*, MSc<sup>1</sup>, Daniel Alcolea\*, MD, PhD<sup>2,3</sup>, Laia Montoliu-Gaya, PhD<sup>1</sup>, Susana
- 5 Fernández, MD<sup>14</sup>, Juan Lantero Rodriguez, PhD<sup>1</sup>, Lucía Maure, MD<sup>2,3,14</sup>, Fernando
- 6 González-Ortiz, MD<sup>1,4</sup>, Bessy Benejam, PhD<sup>2,14</sup>, Michael Turton, PhD<sup>5</sup>, Isabel Barroeta, MD
- 7 PhD<sup>2,3,14</sup>,Peter Harrison, MA<sup>5</sup>, Laura Videla, PhD<sup>2,3,14</sup>,Nicholas J. Ashton, PhD<sup>1,6,7,8</sup>, Alberto
- 8 Lleó, MD PhD<sup>2,3</sup>, Henrik Zetterberg, MD, PhD<sup>1,4,9,10,11,12</sup>, María Carmona-Iragui, MD PhD<sup>2,3,14</sup>,
- 9 Thomas K. Karikari, PhD<sup>1,13</sup>, Juan Fortea#, MD PhD<sup>2,3,14</sup> and Kaj Blennow#, MD, PhD<sup>1,4,15,16</sup>
- 
- 11 <sup>1</sup>Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of
- 12 Gothenburg, Mölndal, Sweden,<br>13 <sup>2</sup>Sant Pau Memory Unit. Hospit
- <sup>2</sup> Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de
- 14 Barcelona, Barcelona, Spain,<br>15 <sup>3</sup>Center for Biomedical Investi
- <sup>3</sup> Center for Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Madrid, Spain, 2
- 16 <sup>4</sup>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden,
- 17 <sup>5</sup> Bioventix Plc, Farnham, GU9 7SX, United Kingdom,
- **18** <sup>6</sup> Centre for Age-Related Medicine, Stavanger University Hospital, Stavanger, Norway,
- 19 <sup>7</sup>NIHR Biomedical Research Centre for Mental Health & Biomedical Research Unit for Dementia at South London & Maudsley NHS<br>- -
- 20 Foundation, London, United Kingdom,<br>21 <sup>8</sup>Department of Old Age Psychiatry. In
- 21 <sup>8</sup>Department of Old Age Psychiatry, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London, London,<br>- -
- 22 United Kingdom,
- 23<br>24 Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, University of
- 24 Wisconsin-Madison, Madison, WI, USA,<br>25 <sup>10</sup>Hong Kong Center for Neurodegenera
- <sup>10</sup>Hong Kong Center for Neurodegenerative Diseases, Clear Water Bay, Hong Kong, China, <sup>11</sup>Department of Neurodegenerative<br>26 Disease, UCL Queen Square Institute of Neurology, University College London, London, United Kin
- 26 Disease, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom,<br>27 <sup>12</sup>UK Dementia Research Institute at UCL London. United Kingdom.
- 1<sup>2</sup>UK Dementia Research Institute at UCL, London, United Kingdom,<br>- - - -
- 1<sup>3</sup> Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA, USA,
- 29 <sup>14</sup> Barcelona Down Medical Center, Fundació Catalana Síndrome de Down, Barcelona, Spain<br>- - - -
- 30 <sup>15</sup> Paris Brain Institute, ICM, Pitié-Salpêtrière Hospital, Sorbonne University, Paris, France<br>- . . . . . . .
- 31 <sup>16</sup>Neurodegenerative Disorder Research Center, Division of Life Sciences and Medicine, and Department of Neurology, Institute on<br>- -
- 32 Aging and Brain Disorders, University of Science and Technology of China and First Affiliated Hospital of USTC, Hefei, P.R. China
- <sup>\*</sup>Przemysław R. Kac and Daniel Alcolea contributed equally as first authors<br>34 #Kai Blennow and Juan Fortea contributed equally as senior authors
- #Kaj Blennow and Juan Fortea contributed equally as senior authors

#### <sup>35</sup>**Abstract**

#### <sup>36</sup>**Background**

<sup>37</sup>All individuals with Down Syndrome (DS) will develop full-blown Alzheimer´s disease (AD) 38 pathology by age 40, decades before the occurrence of sporadic late-onset AD. <sup>39</sup>Understanding this strong biological relation between age and AD pathology risk in DS is 40 important to accelerate diagnostics, disease monitoring, and treatment. Several genes 41 encoded in chromosome 21 including dual-specificity tyrosine phosphorylation-regulated 42 kinase 1A (DYRK1A) have been proven to contribute to the pathology. A recently validated 43 plasma immunoassay to measure tau phosphorylation at threonine-212 (p-tau212) has very <sup>44</sup>high diagnostic accuracy in detecting AD. P-tau212 is also very sensitive to DYRK1A 45 phosphorylation and is increased in DSAD brain lysates. Here, we assessed the potential of 46 this biomarker in DSAD and sporadic AD.

#### <sup>47</sup>**Methods**

<sup>48</sup>Using Simoa technology, we tested p-tau212 and p-tau181 (n=245 for plasma, n=114 <sup>49</sup>matching cerebrospinal fluid (CSF) samples). We used AUC-ROC to examine diagnostic 50 performance and the DeLong test to compare the AUC-ROC differences between methods. 51 Spearman correlation is used to examine correlations. Fold changes relative to median levels 52 were calculated for their respective asymptomatic groups. ANCOVA followed by Tukey post-53 hoc test was used to calculate differences across groups. LOESS was used to determine the 54 temporality of plasma biomarker changes.

## <sup>55</sup>**Results**

<sup>56</sup>We have confirmed that p-tau212 has extremely high accuracy in detecting AD-related 57 changes in euploid controls. For the DS population, we observed a strong correlation 58 between plasma and CSF p-tau212 ( $r=0.867$ ;  $p<0.001$ ). In prodromal DS ( $pDS$ ) and 59 dementia DS (dDS), we observed significantly elevated levels of p-tau212 in reference to



71 Alzheimer's disease; Down Syndrome; plasma biomarkers; p-tau212; DYRK1A; DABNI; 72 SPIN; Simoa; CSF biomarkers.

73

## <sup>74</sup>**Introduction**

75 A triplication of chromosome 21 causes Down syndrome (DS)(1). All individuals with DS 76 develop full-blown Alzheimer's Disease (AD) pathology by age 40(2) and the lifetime risk of 77 developing AD exceeds 90% in the seventh decade(3). The estimated age of onset of AD 78 dementia in this population is 53.8 years, decades before the occurrence of late-onset AD in 79 the general population(4). Understanding this strong DSAD relationship is important to 80 accelerate diagnostics and treatment. This ultra-high risk is mainly due to the triplication of 81 the amyloid precursor protein (*APP*), which leads to the overproduction of amyloid-β (Aβ) 82 peptides, and increased Aβ plaques formation(5). Although other genes encoded in 83 chromosome 21 such as dual-specificity tyrosine phosphorylation-regulated kinase 1A <sup>84</sup>(*DYRK1A*) and *RCAN1* contribute to the pathology(6–9). *DYRK1A* is a dose-sensitive gene

85 that overexpression contributes to DS cognitive dysfunction(10). This protein phosphorylates 86 different targets involved in AD development and progression for instance Glycogen 87 synthase kinase-3β (GSK-3β)(11), Presenilin1(12), APP(6), and tau(13).

89 Diagnosing DSAD is challenging due to the association of DS with cognitive 90 dysfunction(14,15). Recent advances allow us to recognize ante-mortem AD pathology using 91 blood-based biomarkers(16–19). These reflect the disease almost as accurately as more 92 expensive and less available CSF and imaging biomarkers(20). Several plasma p-tau 93 biomarkers have been found to reflect both Aβ and tau pathology(21). Recently validated 94 plasma p-tau212 has shown very high performance for detecting those pathologies and AD 95 diagnosis(22). That phosphorylation site might also have the strongest biological correlation 96 with AD pathology in DS since threonine-212 is a primary target for DYRK1A in tau 97 protein(23). Intensified phosphorylation at thr-212 induces tau aggregation, reduces tau 98 binding to microtubules, and increases cell toxicity in in-vitro studies(24). Levels of p-tau212 99 are highly elevated in reference to AD and control participants in human AD-DS brains(25). <sup>100</sup>Additionally, a major tau phosphatase – Protein phosphatase 1A (PP1A) is not 101 dephosphorylating p-tau212 derived from AD brains(26), suggesting that this epitope might 102 be vulnerable to very subtle changes related to AD pathology. Knowing that direct biological 103 association, we hypothesized that p-tau212 is an accurate tau species to reflect AD 104 pathology in the DS population. To test this hypothesis, we used Single molecule array <sup>105</sup>(Simoa) immunoassays to measure plasma and cerebrospinal fluid (CSF) p-tau212 106 concentrations in asymptomatic DS (aDS), prodromal DS (pDS), and dementia DS (dDS) 107 individuals, as well as in sporadic AD patients both in Mild Cognitive impairment (MCI) and 108 dementia states and we compare the results with a validated biomarker.

110

# <sup>113</sup>**Methods**

## <sup>114</sup>**Study design and participants**

<sup>115</sup>We performed a cross-sectional cohort study of adults with DS, and euploid individuals along 116 the Alzheimer's disease continuum in the Hospital of Sant Pau, Barcelona (Spain), Adults 117 with DS in Barcelona were recruited from a population-based health plan designed to screen 118 for AD dementia, which includes yearly neurological and neuropsychological assessments. 119 Those subjects interested in research studies are included in the Down Alzheimer Barcelona 120 Neuroimaging Initiative (DABNI) cohort(14,15). We also recruited euploid controls and 121 sporadic Alzheimer's disease patients from the Sant Pau Initiative on Neurodegeneration 122 (SPIN cohort)(27).

## <sup>124</sup>**Biomarker measurements**

<sup>125</sup>Amyloid-β peptides (Aβ40, Aβ42) analyses were performed on the LUMIPULSE G600II, and 126 the cut-off for positivity was defined as in the previous publication(28). All other plasma and <sup>127</sup>CSF biomarker assays were performed on the Simoa HD-X platform at the University of 128 Gothenburg. P-tau212 and p-tau181 concentrations were measured using published and 129 validated in-house assays(16,22). For p-tau181, the AT270 antibody (Invitrogen) was used 130 as a capture antibody and was paired with n-terminal antibody for detection (Tau12; 131 BioLegend). For p-tau212, a sheep monoclonal antibody was used for capture paired with 132 Tau12 as the detector. Coefficients of variation for 3 different internal quality controls for 133 plasma were 5.3-12% for within-plate variation and 6.4%-12% for between-plate variation. 134 For CSF, these values were 10.8%-13.3% and 12.9%-15.5%, respectively.

135

#### <sup>136</sup>**Statistical Analysis:**

137 We used AUC-ROC to examine diagnostic performance and the DeLong test to compare the <sup>138</sup>AUC-ROC differences between methods. Spearman correlation is used to examine

139 correlations. Fold changes relative to median levels are calculated for their respective 140 asymptomatic groups. Age-adjusted analysis of covariance (ANCOVA) followed by Tukey 141 post-hoc test is used to calculate differences across groups. A First-degree locally estimated 142 scatterplot smoothing curve (LOESS) is independently used in controls and adults with Down 143 Syndrome to determine the temporality of plasma biomarker changes. For Down participants <sup>144</sup>we set the mean age of symptoms onset at 53.8 years according to a previous study from 145 our group(29). All significance tests were two-sided, and significance was set at  $p<0.05$ .

# <sup>147</sup>**Results**

#### <sup>148</sup>**Cohort characteristics**

<sup>149</sup>We tested n=245 plasma samples for p-tau212 and p-tau181. A subset of participants had 150 amyloid PET data. Table 1. shows the demographics, cognitive, and plasma biomarkers 151 across groups of all participants included in the analyses. N=114 (47%) participants had CSF 152 biomarker measurements. Demographics for the CSF subset are shown in Supplementary 153 Table 1.

154

#### <sup>155</sup>**Correlations with biomarkers and cognition**

156 Plasma and CSF p-tau212 were highly correlated with each other within the cohort. We 157 observed moderate correlation across sample types in all participants (r=0.712 p<0.0001) <sup>158</sup>(Fig. 1A). However, the strongest correlation of plasma p-tau212 with CSF p-tau212 was 159 observed in the DS-only subgroup (r=0.867, p<0.0001) (Fig 1A). This improved CSF-plasma 160 correlation in DS groups was not seen for p-tau181, which showed similar correlations in the 161 whole cohort and subgroups ( $r=0.652-0.681$ ,  $p<0.0001$ ) (Fig 1B). Those results indicate that 162 plasma p-tau212 measurements accurately reflect AD-related p-tau level changes in CSF in 163 sporadic and DS groups.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.10.31.24316469;](https://doi.org/10.1101/2024.10.31.24316469) this version posted November 2, 2024. The copyright holder for this preprint

<sup>165</sup>**Figure 1. Spearman correlations for plasma and CSF p-tau212 and p-tau181**. The Figure 166 shows correlations between plasma and CSF for **A)** p-tau212 and **B)** p-tau181 for euploid<br>167 groups (n=88; p<0.001; r= 0.701 and r=0.660 respectively) and DS groups (n=26, p<0.001; 167 groups (n=88; p<0.001; r= 0.701 and r=0.660 respectively) and DS groups (n=26, p<0.001;<br>168 r=0.867, r=0,681 respectively). The correlation between plasma and CSF measurements for 168 r=0.867, r=0,681 respectively). The correlation between plasma and CSF measurements for<br>169 all measurements (n=114, p<0.001) is 0.712 for p-tau212 and 0.652 for p-tau181. The fitted 169 all measurements (n=114, p<0.001) is 0.712 for p-tau212 and 0.652 for p-tau181. The fitted 170 simple linear regression line is presented as a mean and error. 170 simple linear regression line is presented as a mean and error.<br>171

171 Both biomarkers were correlated with decrease in The Cambridge Cognitive Examination

173 adapted for individuals with Down Syndrome (CAMCOG-DS) in plasma (r=-0.338; p=0.001

174 for p-tau212 and r=-0.328 for p-tau181; p=0.002;) and in CSF (r=-0.686; p<0.001 for p-

175 tau212; and  $r = -0.511$ ; p $<0.001$  for p-tau181).

## <sup>177</sup>**Plasma p-tau212 levels are increased in asymptomatic Down syndrome**

178 Plasma p-tau212 concentration was 2.4x times higher in the aDS group compared with 179 cognitively normal (CN) euploid people (p<0.001) whereas plasma p-tau181 was not 180 significantly changed ( $p=0.052$ ).

181

#### <sup>182</sup>**Plasma and CSF p-tau212 increase along the AD continuum in DSAD and sporadic AD**

183 Both in individuals with DS and euploid participants, p-tau212 levels were increased in 184 symptomatic patients in comparison with asymptomatic individuals. (Fig. 2A). For pDS we 185 observed a 3.4x ( $p=0.003$ ) mean fold increase in plasma and a 5.6x mean fold-fold increase 186 in CSF in reference to aDS. For dDS we observed a 2.9x ( $p=0.004$ ) mean fold increase in 187 plasma and a 7.1x mean fold increase in CSF. For MCI-AD, compared with cognitively 188 normal euploid people, we observed a  $3.0x$  (p $< 0.001$ ) mean fold increase in plasma and a 189 7.8x mean fold increase in CSF. AD dementia patients had a 3.8x mean fold increase in 190 plasma ( $p$ <0.001) and a 9.1x mean fold increase in CSF. P-tau181 concentrations were also 191 increased, but with a lower magnitude than p-tau212, and comparison between DS groups 192 showed no significance (Fig. 2B). Both biomarkers kept the pattern of greater increases in 193 CSF than in plasma (Supplementary Fig. 1A-B).

194<br>195

<sup>195</sup>**Figure 2. Plasma p-tau212 and p-tau181 levels in euploid and Down Syndrome (DS)**  196 **groups.** Box plots represent median and IQR, and boundaries of the whiskers are minimum<br>197 to maximum values for A) plasma p-tau212 and B) plasma p-tau181. Differences for euploid <sup>197</sup>to maximum values for **A)** plasma p-tau212 and **B)** plasma p-tau181. Differences for euploid

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.10.31.24316469;](https://doi.org/10.1101/2024.10.31.24316469) this version posted November 2, 2024. The copyright holder for this preprint

198 barticipants are calculated for Mild Cognitively impaired Alzheimer's Disease (MCI-AD; n=62)<br>199 band Alzheimer's Disease Dementia (AD: n=20) in reference to Cognitively Normal (CN: 199 and Alzheimer's Disease Dementia (AD; n=20) in reference to Cognitively Normal (CN;<br>200 n=46) participants. Differences for prodromal Alzheimer's Disease in DS (pDS: n=8) and 200 n=46) participants. Differences for prodromal Alzheimer's Disease in DS (pDS; n=8) and<br>201 Alzheimer's Disease dementia in DS (dDS; n=17) are calculated in reference to 201 Alzheimer's Disease dementia in DS (dDS; n=17) are calculated in reference to<br>202 asymptomatic (aDS; n=92). Age-adjusted analysis of covariance (ANCOVA) followed by 202 asymptomatic (aDS; n=92). Age-adjusted analysis of covariance (ANCOVA) followed by<br>203 Tukey post-hoc test is used to calculate differences across groups. 203 Tukey post-hoc test is used to calculate differences across groups.<br>204

# <sup>205</sup>**Plasma p-tau212 has greater diagnostic accuracy than p-tau181**

206 ROC analysis was used to evaluate the diagnostic performance of plasma and CSF p-tau212 207 and p-tau181. AUCs were usually higher for biomarkers in CSF, and for p-tau212 than for p-

- 208 tau181. In our comparisons, we included Age+ Apolipoprotein E4 (APOE4)+Sex since they
- 209 have been shown to influence diagnostic accuracy(30). AUCs of Age+APOE+Sex were not
- 210 significantly different from p-tau212 but better than p-tau181. Both biomarkers had high
- 
- 211 accuracy to differentiate between CN and AD in plasma  $AUC = 0.96$  (95% CI 0.92-1) for p-
- 212 tau212 and AUC =  $0.89$  (95% CI 0.84-0.95) for p-tau181 (Fig. 3B). For differentiating
- 213 between CN and MCI-AD (Fig. 3A) or MCI-AD+AD (Fig. 3C), p-tau212 had accuracy of 0.91
- <sup>214</sup>(95% CI 0.85-0.97) and AUC=0.93 [95% CI 0.88-0.97] respectively. That accuracy was
- 215 significantly higher than p-tau181 ( $p=0.026$  for both comparisons). Plasma p-tau212
- 216 reached AUC=0.91 (95% CI 0.86-0.97) to differentiate between aDS and dDS diagnosis (Fig.
- 217 3D).
- 218

<sup>219</sup>**Figure 3. Diagnostic accuracy of plasma and CSF biomarkers to discriminate between**  <sup>220</sup>**sporadic and DSAD groups.** P-tau212 and p-tau181 receiver operating characteristic 221 curves (ROC) to discriminate between sporadic and DSAD groups. Plasma p-tau181, plasma<br>222 p-tau212, CSF p-tau181, CSF p-tau212, and Age+APOE+Sex are on each graph. In A) ROC 222 p-tau212, CSF p-tau181, CSF p-tau212, and Age+APOE+Sex are on each graph. In **A**) ROC<br>223 curves for differentiating Cognitively normal (CN) and Mild Cognitive Impairment -223 curves for differentiating Cognitively normal (CN) and Mild Cognitive Impairment -<br>224 DAIzheimer's Dementia (MCI-AD). B) ROC curves to discriminate between CN and 224 Alzheimer's Dementia (MCI-AD). **B**) ROC curves to discriminate between CN and<br>225 Alzheimer's Disease (AD). **C**) ROC curves to differentiate between CN and MCI-AD 225 Alzheimer's Disease (AD). **C**) ROC curves to differentiate between CN and MCI-AD<br>226 combined with AD group. **D**) ROC curves to discriminate between asymptomatic Down 226 combined with AD group. **D**) ROC curves to discriminate between asymptomatic Down<br>227 syndrome (aDS) and prodromal Down Syndrome (pDS) + dementia Down syndrome (dDS). 227 syndrome (aDS) and prodromal Down Syndrome (pDS) + dementia Down syndrome (dDS).<br>228

# <sup>229</sup>**Plasma p-tau212 increases approximately parallel to amyloid PET positivity and has**

# <sup>230</sup>**great accuracy in discriminating between A**β**+ and A**β**- participants**

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.10.31.24316469;](https://doi.org/10.1101/2024.10.31.24316469) this version posted November 2, 2024. The copyright holder for this preprint

231 Both biomarkers had significant accuracy in discriminating between  $\mathsf{A}\mathsf{B}$ + and  $\mathsf{A}\mathsf{B}$ - participants

<sup>232</sup>(Fig. 4). Plasma p-tau212 had numerically higher accuracy than p-tau181 both for DS (AUC

233 = 0.86 (95%CI = 0.7-1) (Fig. 4B) and euploid participants AUC = 0.9 (0.83 – 0.96) (Fig. 4C).

234<br>235

<sup>235</sup>**Figure 4. Diagnostic accuracy of plasma and CSF biomarkers to discriminate between**  <sup>236</sup>**A**β**+ and A**β**- participants.** P-tau212 and p-tau181 receiver operating characteristic curves 237 (ROC) to discriminate between amyloid positive (Aβ+) and amyloid negative (Aβ-)<br>238 participants in sporadic and DSAD groups. Plasma p-tau181, plasma p-tau212, CSF p-238 participants in sporadic and DSAD groups. Plasma p-tau181, plasma p-tau212, CSF p-<br>239 tau181, CSF p-tau212, and Age+APOE+Sex are on each graph. In A) ROC curves for 239 tau181, CSF p-tau212, and Age+APOE+Sex are on each graph. In **A**) ROC curves for<br>240 differentiating Aß+ from Aß- in whole cohort. **B**) ROC curves to discriminate Aß+ and Aß- in 240 differentiating Aβ+ from Aβ- in whole cohort. **B**) ROC curves to discriminate Aβ+ and Aβ- in<br>241 DS groups. **C**) ROC curves to differentiate between Aβ+ and Aβ- in euploid groups. <sup>241</sup>DS groups. **C**) ROC curves to differentiate between Aβ+ and Aβ- in euploid groups.

243 An early increase in plasma levels was observed many years before the onset of clinical AD

- 244 symptoms in DS (Fig 5). For p-tau212 the increase started approximately when people
- <sup>245</sup>became amyloid PET-positive, *i.e.*, in their late 30s, and approximately 15 years before the
- 246 disease onset (Fig. 5A). P-tau181 started increasing approximately 10 years before the
- 247 estimated disease onset (Fig. 5B).
- 

<sup>249</sup>**Figure 5. Age-related plasma p-tau212 and p-tau181 changes in Down syndrome and**  <sup>250</sup>**euploid controls.** Open Circles represent asymptomatic and filled circles represent 251 symptomatic participants. Down syndrome population is represented in red and cognitively<br>252 normal euploid people are represented in blue. Horizontal lines depict each group's fitted 252 normal euploid people are represented in blue. Horizontal lines depict each group's fitted<br>253 loess model, and fainted bands display confidence intervals. The vertical red line represents 253 loess model, and fainted bands display confidence intervals. The vertical red line represents<br>254 the estimated years to symptom onset which is 53.8 for Down syndrome participants and 254 the estimated years to symptom onset which is 53.8 for Down syndrome participants and<br>255 was used as reference in euploid controls for comparison purposes. 255 was used as reference in euploid controls for comparison purposes.<br>256

#### <sup>257</sup>**Discussion**

258 In this cross-sectional study, we show that p-tau212 serves as a biomarker to track AD-

- 259 related changes in sporadic cases and DSAD. P-tau212 has a very high correlation between
- 260 plasma and CSF. The strongest correlation was observed for the DS population, where p-
- 261 tau212 reached a greater correlation than for euploid participants. For p-tau181 correlation in
- 262 euploid and DS groups was similar, suggesting greater translation from CSF to plasma for p-
- 263 tau212 in DS populations.

<sup>265</sup>We observed elevated p-tau212 concentration in plasma and CSF in aDS compared with 266 euploid CN. That elevation is greater than the p-tau181 elevation, which did not reach 267 statistical significance. Additionally, other reported biomarkers, such as p-tau217 Glial 268 fibrillary acidic protein (GFAP)(30,31), had lower increases. This suggests the effects of 269 DYRK1A gene dose interacting with AD pathology on p-tau212 levels in DS and a better fit 270 for the use of this biomarker in the DS population.

<sup>272</sup>Levels of plasma p-tau212 were significantly higher across disease groups. Plasma p-tau212 273 reached significance levels to differentiate between aDS vs pDS and aDS vs dDS groups 274 while p-tau181 failed to do it. However, we think this might be a limitation of the small sample 275 size used in this cohort since p-tau181 levels were previously shown to be significantly 276 increased in pDS and aDS(30,32). In MCI-AD and AD dementia groups, we observed 277 significant increases for both biomarkers, concomitantly having fold changes higher for p-278 tau212 which confirms our previous findings(22).

280 The excellent performance of the assay was confirmed in discriminating patients according to 281 the diagnosis in both DS and euploid groups. P-tau212 additionally has greater accuracy 282 than p-tau181 in discriminating between MCI-AD and control groups, simultaneously 283 reaching 0.96 AUC to differentiate CN from AD. Additionally, plasma p-tau212 acquired very 284 high AUC-ROC in discriminating between Aβ+ and Aβ- participants in both euploid and DS 285 groups. This accuracy was not different from CSF accuracy, supporting the high between-286 matrix translation of p-tau212 and providing additional reasoning to use plasma p-tau212 to 287 recruit participants for clinical trials.

289 Plasma p-tau212 starts increasing in the 30s, approximately when people start being positive 290 in amyloid PET scans, and 5 years before we observe an increase in p-tau181. Additionally, 291 the biomarker increased further as AD progressed towards symptomatic stages. Therefore p-292 tau212 could be useful to monitor the progression of asymptomatic DS people to prodromal

293 AD. Moreover, the onset of the increase comes along with the appearance of neurofibrillary 294 tangles (NFTs) and Aβ plaques in brain(4,33).

295

296 This is (to our best knowledge) the first study to measure p-tau212 in CSF and plasma as a 297 biomarker for DSAD however, the potential involvement of p-tau212 in this population and its 298 association with DYRK1A was published more than 20 years ago(13). The kinase is 299 perceived as a target in DS and neurodegenerative diseases(8,34). Its under- or 300 overexpression leads to different clinical phenotypes including cognitive impairment(34). 301 Since DYRK1A is a dose-sensitive protein in which down-regulation or up-regulation has a 302 critical role, DYRK1A inhibitors have already been widely explored in clinical trials and have 303 been proven to improve cognitive function in DS people(10,35,36). Importantly, p-tau212 has 304 already been successfully used to test the efficacy of DYRK1A inhibitor in cell models(37). 305 The use of the chosen inhibitor was further shown to reverse the upregulation of p-tau212 in 306 hippocampal tissue and temporal cortex in mouse models(37). Our novel plasma p-tau212 307 immunoassay provides a simple-to-implement and cost-effective opportunity to monitor the  $308$  efficacy of DYRK1A inhibitors, or in the future – enhancers, not allowing the activity of this 309 kinase to be reduced or increased to levels that could cause more harm than good. This 310 utility will be explored in our future research.

311

312 The major strength of this study is the confirmation that p-tau212 is increased in the DS 313 population, and levels of this biomarker increase with progression to AD dementia. P-tau212 314 reaches very high accuracy to differentiate between control and disease groups and  $\beta$ + and <sup>315</sup>Aβ- participants. The high correlation between plasma and CSF p-tau212 also supports a 316 very high translation of the results from CSF to plasma. DeLong tests between DS groups 317 did not show any significantly better performance of CSF p-tau212 compared with plasma p-318 tau212 providing further evidence that plasma measurements can be used for clinical 319 evaluation of AD pathophysiological processes occurring in patients with suspected disease. 320 Advantages would also be reflected in the economy, availability, and perception of the test,

321 since lumbar punctures or PET scans are costly, require resources, and might be perceived 322 as frightening(20). Next, plasma p-tau212 increased approximately when people are starting 323 to be amyloid PET positive and 5 years before p-tau181, indicating the benefits in disease 324 monitoring.

326 This study has a few limitations. First is a slightly low representation of prodromal-DS 327 participants, which prohibits us from making better AUC-ROC analysis in that group. Ideally, 328 Iongitudinal measurements of p-tau212 in the DS population would tell us more about the 329 trajectories of this biomarker. The second limitation is that p-tau217 measurements are 330 unavailable at the moment, however direct comparison between biomarkers was not a 331 purpose of experiments presented in this article. Still, p-tau181 is the most commercialized 332 and fully automated immunoassay, with great utility in AD.

333

## <sup>334</sup>**Conclusions**

335 In conclusion, we have confirmed that levels of plasma p-tau212 are increased in the DS 336 population and sporadic AD cases including prodromal and MCI states. High accuracy in 337 discriminating amyloid positive from amyloid negative people and increase in parallel to 338 amyloid-PET positivity give the promise to evaluate ongoing pathophysiological AD 339 processes many years before the disease onset in individuals with DS. This will also facilitate 340 participants recrutation for clinical trials. This is a cost-effective application that provides 341 higher chance to receive appropriate therapy. Plasma p-tau212 will also find high utility for 342 theragnostic, to monitor therapy efficacy, and as a target engagement biomarker in clinical 343 trials both in sporadic and DSAD.

344

#### <sup>345</sup>**Abbreviations**

346 AD: Alzheimer's disease

- 347 DS: Down Syndrome
- 348 DYRK1A: dual-specificity tyrosine phosphorylation-regulated kinase 1A
- $349$  p-tauX: tau phosphorylated at amino acid X
- 350 DSAD Down Syndrome Alzheimer's disease
- 351 CSF Cerebrospinal Fluid
- 352 AUC-ROC: Area Under the Curve and Receiver Operating Curves
- 353 ANCOVA: Age-adjusted analysis of covariance
- 354 LOESS: locally estimated scatterplot smoothing
- 355 pDS: prodromal Down syndrome
- 356 aDS: asymptomatic Down syndrome
- 357 dDS: dementia Down syndrome
- 358 PET: Positron Emission Tomography
- <sup>359</sup>MCI: mild cognitive impairment
- 360 Aβ: amyloid beta
- 361 APP: amyloid precursor protein
- 362 GSK-3β: Glycogen synthase kinase-3β
- 363 PP1A: Protein phosphatase 1A
- 364 DABNI: Down Alzheimer Barcelona Neuroimaging Initiative
- 365 SPIN: Sant Pau Initiative on Neurodegeneration

- 366 CN: cognitively normal
- 367 IQR; interquartile range
- 368 SD: standard deviation
- <sup>369</sup>CAMCOG-DS: The Cambridge Cognitive Examination adapted for individuals with Down
- 370 Syndrome
- 371 APOE4: Apolipoprotein E4
- <sup>372</sup>GFAP: Glial fibrillary acidic protein
- 373 NFTs: Neurofibrillary tangles

# <sup>375</sup>**Declarations**

# <sup>376</sup>**Ethics approval and consent to participate**

377 Study procedures were approved by the Sant Pau Ethics Committee (IIBSP-NGF-2018-36 378 and IIBSP-DOW-2014-30), following the standards for medical research in humans, as 379 recommended in the Declaration of Helsinki. All participants or their legally authorized 380 representative gave written informed consent before enrolment.

381

# <sup>382</sup>**Consent for publication**

383 Not applicable

# <sup>385</sup>**Availability of data and materials**

386 Blinded Anonymized data is available on reasonable request from the corresponding author.

387 Request will be reviewed by the investigators and respective institutions to verify if data

- 388 transfer is in the agreement with EU legislation on the general data protection or is subject to
- 389 any intellectual property or confidentiality obligations.

# <sup>391</sup>**Competing interests**

<sup>392</sup>MT and PH are employees of Bioventix Plc. HZ has served at scientific advisory boards 393 and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Amylyx, Annexon, <sup>394</sup>Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, <sup>395</sup>LabCorp, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon <sup>396</sup>Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens 397 Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by <sup>398</sup>Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, and Roche, and is a co-founder 399 of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures 400 Incubator Program (outside submitted work). KB has served as a consultant or at advisory <sup>401</sup>boards for Abcam, Axon, BioArctic, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, 402 Novartis, Ono Pharma, Pharmatrophix, Prothena, Roche Diagnostics, and Siemens 403 Healthineers. HZ and KB are co-founders of Brain Biomarker Solutions in Gothenburg AB, a <sup>404</sup>GU Ventures-based platform company at the University of Gothenburg. D.A. participated in 405 advisory boards from Fujirebio-Europe, Roche Diagnostics, Grifols S.A. and Lilly, and 406 received speaker honoraria from Fujirebio-Europe, Roche Diagnostics, Nutricia, Krka 407 Farmacéutica S.L., Zambon S.A.U. and Esteve Pharmaceuticals S.A. D.A. and JF declare a 408 filed patent application (licensed to Adx, EPI8382175 J.F. reported receiving personal fees 409 for service on the advisory boards, adjudication committees or speaker honoraria from AC 410 Immune, Adamed, Alzheon, Biogen, Eisai, Esteve, Eisai, Fujirebio, Ionis, Laboratorios 411 Carnot, Lilly, Life Molecular Imaging, Lundbeck, Perha, Roche, and, outside the submitted 412 work. The other authors declare no competing interest.

413

#### <sup>414</sup>**Funding**

415 PRK was funded by Demensförbundet and Anna Lisa and Brother Björnsson's Foundation. <sup>416</sup>LMG is supported by the Brightfocus Foundation (A2022015F), the Swedish Dementia

417 Foundation, Gun and Bertil Stohnes Foundation, Åhlén-stifelsen, Alzheimerfonden (AF-<sup>418</sup>968621) and Gamla Tjänarinnor Foundation. FG-O was funded by the Anna Lisa and Brother <sup>419</sup>Björnsson's Foundation. HZ is a Wallenberg Scholar and a Distinguished Professor at the 420 Swedish Research Council supported by grants from the Swedish Research Council (#2023-<sup>421</sup>00356; #2022-01018 and #2019-02397), the European Union's Horizon Europe research and 422 innovation programme under grant agreement No 101053962, Swedish State Support for 423 Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), 424 USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-<sup>425</sup>21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C, and #ADSF-24-1284328-C), the 426 Bluefield Project, Cure Alzheimer's Fund, the Olav Thon Foundation, the Erling-Persson <sup>427</sup>Family Foundation, Familjen Rönströms Stiftelse, Stiftelsen för Gamla Tjänarinnor, <sup>428</sup>Hjärnfonden, Sweden (#FO2022-0270), the European Union's Horizon 2020 research and 429 innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 <sup>430</sup>(MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research <sup>431</sup>(JPND2021-00694), the National Institute for Health and Care Research University College 432 London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at <sup>433</sup>UCL (UKDRI-1003). KB is supported by the Swedish Research Council (#2017-00915 and <sup>434</sup>#2022-00732), the Swedish Alzheimer Foundation (#AF-930351, #AF-939721, #AF-968270, 435 and #AF-994551), Hjärnfonden, Sweden (#FO2017-0243 and #ALZ2022-0006), the Swedish 436 state under the agreement between the Swedish government and the County Councils, the 437 ALF-agreement (#ALFGBG-715986 and #ALFGBG-965240), the European Union Joint 438 Program for Neurodegenerative Disorders (JPND2019-466-236), the Alzheimer's Association <sup>439</sup>2021 Zenith Award (ZEN-21-848495), the Alzheimer's Association 2022-2025 Grant (SG-23- 440 1038904 QC), La Fondation Recherche Alzheimer (FRA), Paris, France, the Kirsten and 441 Freddy Johansen Foundation, Copenhagen, Denmark, and Familjen Rönströms Stiftelse, 442 Stockholm, Sweden. TKK was supported by the NIH (R01 AG083874, RF1 AG052525-01, <sup>443</sup>P30 AG066468-04, R01 AG053952, R01 MH121619, R37 AG023651, RF1 AG025516-12A1, <sup>444</sup>R01 AG073267, R01 MH108509, R01 AG075336, R01 AG072641, P01 AG025204), the

445 Swedish Research Council (Vetenskåpradet; #2021-03244), the Alzheimer's Association (#AARF-21-850325), the Swedish Alzheimer Foundation (Alzheimerfonden), the Aina (Ann) Wallströms and Mary-Ann Sjöbloms stiftelsen, and the Emil och Wera Cornells stiftelsen. J.F 448 was supported by the Fondo de Investigaciones Sanitario, Carlos III Health Institute (INT21/00073, PI20/01473 and PI23/01786) and the Centro de Investigación Biomédica en 450 Red sobre Enfermedades Neurodegenerativas Program 1, partly jointly funded by Fondo Europeo de Desarrollo Regional, Unión Europea, Una Manera de Hacer Europa. This work 452 was also supported by the National Institutes of Health grants (R01 AG056850; R21 AG056974, R01 AG061566, R01 AG081394 and R61AG066543), the Department de Salut de la Generalitat de Catalunya, Pla Estratègic de Recerca i Innovació en Salut (SLT006/17/00119). It was also supported by Fundación Tatiana Pérez de Guzmán el Bueno (IIBSP-DOW-2020-151) and Horizon 2020–Research and Innovation Framework Programme 457 from the European Union (H2020-SC1-BHC-2018-2020).

## <sup>459</sup>**Authors' contributions**

<sup>460</sup>PRK, DA, NJA, HZ, TKK, JF and KB created the concept and design. Data acquisition and 461 analysis was performed by PRK, DA, LMG, JLR, NJA, JF. SF, LM, BB, MT, IB, PH, LV, AL, <sup>462</sup>MC-I contributed to the sample selection/and or interpretation of the data. PKK, DA, LMG, 463 JLR, FG-O, HZ, TKK, JF and KB drafted the manuscript, and all authors revised. All authors 464 read and approved the final manuscript.

## <sup>466</sup>**Acknowledgements**

<sup>467</sup>We thank all the participants with Down syndrome, their families, and their carers for their 468 support of, and dedication to this research. We also acknowledge Fundació Catalana 469 Síndrome de Down for global support and the members of the Alzheimer Down Unit and the 470 Memory Unit from Hospital de la Santa Creu i Sant Pau for their daily work and dedication.

471

## <sup>472</sup>**References**



<sup>496</sup>expression of GSK-3beta. FEBS J. 2006 May;273(10):2100–9.



- 498 Neurodevelopmental Disorders, Is a Target for Drug Development in Down Syndrome.
- <sup>499</sup>Front Behav Neurosci [Internet]. 2016 [cited 2021 Jul 14];10. Available from:
- <sup>500</sup>https://www.frontiersin.org/articles/10.3389/fnbeh.2016.00104/full#B228
- 501 11. Skurat AV, Dietrich AD. Phosphorylation of Ser640 in muscle glycogen synthase by
- 502 DYRK family protein kinases. J Biol Chem. 2004 Jan 23;279(4):2490–8.
- <sup>503</sup>12. Ryu YS, Park SY, Jung MS, Yoon SH, Kwen MY, Lee SY, et al. Dyrk1A-mediated
- 504 phosphorylation of Presenilin 1: a functional link between Down syndrome and
- <sup>505</sup>Alzheimer's disease. J Neurochem. 2010;115(3):574–84.
- 506 13. Woods YL, Cohen P, Becker W, Jakes R, Goedert M, Wang X, et al. The kinase DYRK
- 507 phosphorylates protein-synthesis initiation factor eIF2Bepsilon at Ser539 and the
- <sup>508</sup>microtubule-associated protein tau at Thr212: potential role for DYRK as a glycogen

509 synthase kinase 3-priming kinase. Biochem J. 2001 May 1;355(Pt 3):609–15.

- 510 14. Fortea J, Carmona-Iragui M, Benejam B, Fernández S, Videla L, Barroeta I, et al. Plasma
- <sup>511</sup>and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down
- 512 syndrome: a cross-sectional study. Lancet Neurol. 2018 Oct 1;17(10):860–9.
- 513 15. Fortea J, Vilaplana E, Carmona-Iragui M, Benejam B, Videla L, Barroeta I, et al. Clinical
- 514 and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-

515 sectional study. The Lancet. 2020 Jun 27;395(10242):1988–97.

- <sup>516</sup>16. Karikari TK, Pascoal TA, Ashton NJ, Janelidze S, Benedet AL, Rodriguez JL, et al. Blood
- 517 phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic
- 518 performance and prediction modelling study using data from four prospective cohorts.
- 519 Lancet Neurol. 2020 May; 19(5): 422–33.



- 521 Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other
- 522 Neurodegenerative Disorders. JAMA. 2020 Aug 25;324(8):772-81.
- 523 18. Ashton NJ, Pascoal TA, Karikari TK, Benedet AL, Lantero-Rodriguez J, Brinkmalm G, et
- 524 al. Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology. Acta
- 525 Neuropathol (Berl). 2021 May 1;141(5):709-24.
- 526 19. Kac PR, Gonzalez-Ortiz F, Simrén J, Dewit N, Vanmechelen E, Zetterberg H, et al.
- 527 Diagnostic value of serum versus plasma phospho-tau for Alzheimer's disease.
- 528 Alzheimers Res Ther. 2022 May 11;14(1):65.
- 529 20. Gonzalez-Ortiz F, Kac PR, Brum WS, Zetterberg H, Blennow K, Karikari TK. Plasma
- 530 phospho-tau in Alzheimer's disease: towards diagnostic and therapeutic trial
- 531 applications. Mol Neurodegener. 2023 Mar 16;18(1):18.
- 532 21. Mattsson-Carlgren N, Janelidze S, Bateman RJ, Smith R, Stomrud E, Serrano GE, et al. -Carlgren N, Janelidze S, Bateman RJ, Smith R, Stomrud E, Serrano GE, et al.<br>-<br>-tau217 reflects amyloid and tau pathology and mediates the association of
- 533 Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of<br>534 amyloid with tau. EMBO Mol Med. 2021 Jun 8;13(6):e14022.
- 534 amyloid with tau. EMBO Mol Med. 2021 Jun 8:13(6):e14022.
- <sup>535</sup>22. Kac PR, González-Ortiz F, Emeršič A, Dulewicz M, Koutarapu S, Turton M, et al. Plasma
- 536 p-tau212 antemortem diagnostic performance and prediction of autopsy verification of
- 537 Alzheimer's disease neuropathology. Nat Commun. 2024 Mar 23;15(1):2615.
- <sup>538</sup>23. Liu F, Liang Z, Wegiel J, Hwang YW, Iqbal K, Grundke-Iqbal I, et al. Overexpression of 539 Dyrk1A contributes to neurofibrillary degeneration in Down syndrome. FASEB J. 2008 540 Sep;22(9):3224–33.
- 541 24. Alonso AD, Di Clerico J, Li B, Corbo CP, Alaniz ME, Grundke-Iqbal I, et al.
- 542 Phosphorylation of Tau at Thr212, Thr231, and Ser262 Combined Causes
- 543 Neurodegeneration. J Biol Chem. 2010 Oct 1;285(40):30851–60.



- 547 26. Rahman A, Grundke-Iqbal I, Iqbal K. Phosphothreonine-212 of Alzheimer abnormally
- 548 hyperphosphorylated tau is a preferred substrate of protein phosphatase-1. Neurochem
- 549 Res. 2005 Feb;30(2):277-87.
- <sup>550</sup>27. Alcolea D, Clarimón J, Carmona-Iragui M, Illán-Gala I, Morenas-Rodríguez E, Barroeta I,
- 551 et al. The Sant Pau Initiative on Neurodegeneration (SPIN) cohort: A data set for
- 552 biomarker discovery and validation in neurodegenerative disorders. Alzheimers Dement

553 N Y N. 2019;5:597–609.

- 554 28. Alcolea D, Pegueroles J, Muñoz L, Camacho V, López-Mora D, Fernández-León A, et al.
- 555 Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse.

556 Ann Clin Transl Neurol. 2019 Sep;6(9):1815–24.

- <sup>557</sup>29. Iulita MF, Garzón Chavez D, Klitgaard Christensen M, Valle Tamayo N, Plana-Ripoll O,
- 558 Rasmussen SA, et al. Association of Alzheimer Disease With Life Expectancy in People

<sup>559</sup>With Down Syndrome. JAMA Netw Open. 2022 May 23;5(5):e2212910.

- 560 30. Montoliu-Gaya L, Alcolea D, Ashton NJ, Pegueroles J, Levin J, Bosch B, et al. Plasma 561 and cerebrospinal fluid glial fibrillary acidic protein levels in adults with Down syndrome:
- 

562 a longitudinal cohort study. eBioMedicine. 2023 Mar 30;90:104547.

- 563 31. Janelidze S, Christian BT, Price J, Laymon C, Schupf N, Klunk WE, et al. Detection of
- <sup>564</sup>Brain Tau Pathology in Down Syndrome Using Plasma Biomarkers. JAMA Neurol. 2022
- 565 Aug 1;79(8):797–807.



- 567 Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer's disease in
- 568 adults with Down syndrome. Nat Commun. 2021 Jul 14;12(1):4304.
- <sup>569</sup>33. Lott IT, Head E. Dementia in Down syndrome: unique insights for Alzheimer disease
- 570 research. Nat Rev Neurol. 2019 Mar;15(3):135–47.
- 571 34. Deboever E, Fistrovich A, Hulme C, Dunckley T. The Omnipresence of DYRK1A in
- 572 Human Diseases. Int J Mol Sci. 2022 Aug 19:23(16):9355.
- <sup>573</sup>35. Murphy AJ, Wilton SD, Aung-Htut MT, McIntosh CS. Down syndrome and DYRK1A
- 574 overexpression: relationships and future therapeutic directions. Front Mol Neurosci. 2024
- 575 Jul 24;17:1391564.
- 576 36. De la Torre R, De Sola S, Pons M, Duchon A, de Lagran MM, Farré M, et al.
- <sup>577</sup>Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down
- 578 syndrome mouse models and in humans. Mol Nutr Food Res. 2014 Feb;58(2):278–88.
- 579 37. Chen H, Gao X, Li X, Yu C, Liu W, Qiu J, et al. Discovery of ZJCK-6-46: A Potent,
- 580 Selective, and Orally Available Dual-Specificity Tyrosine Phosphorylation-Regulated
- 581 Kinase 1A Inhibitor for the Treatment of Alzheimer's Disease. J Med Chem. 2024 Aug
- <sup>582</sup>8;67(15):12571–600.

# $\frac{1}{20}$ <br>  $\frac{1$ 0<sup>-</sup> **1000 2000 3000 P-tau212 Spearman correlation Plasma p-tau212, pg/ml CSF p-tau212, pg/ml r=0.7012 (95% CI 0.5722 - 0.7963) -o**- Euploid groups **r=0.8674 (95% CI 0.7170 - 0.9406) -●** DS groups

# **P-tau181 Spearman Correlation**

**r=0.6602 (95% CI 0.5185 - 0.7666)−o−** Euploid groups **r=0.6807 (95% CI 0.3882 - 0.8486) → DS groups** 









**C** Amyloid − (Euploid) vs. Amyloid + (Euploid)



**A**



Estimated Years to Onset (years)

# **Table 1. Study Participants**



aDS – asymptomatic Down syndrome; pDS – prodromal Down syndrome; dDS – dementia Down syndrome; CN – cognitively normal; MCI-AD – mild cognitive impairment due to Alzheimer's Disease; AD – Alzheimer's disease dementia; IQR – interquartile range; SD – standard deviation. CAMCOG-DS The Cambridge Cognitive Examination adapted for individuals with Down Syndrome